James Love's blog | Knowledge Ecology International

Is the WHO CEWG proposal for the R&D treaty “too small”?

Posted on May 4, 2012 by James Love

The WHO’s Consultative Expert Working Group (CEWG) on R&D proposal for a new WHO Convention on health R&D has been widely praised by public health groups (See https://www.keionline.org/node/1399). The CEWG proposal for a treaty has also, at least so far, avoided much criticism from the pharmaceutical industry, even though it strongly embraces the notion of delinkage of R&D costs from product prices, open innovation, and technology transfer and capacity building in developing countries. Continue Reading →

USTR’s 2012 Special 301 Report, focuses on largest developing country markets, and Canada

Posted on May 1, 2012 by James Love

The 2012 USTR Special 301 Report was published on April 30, 2012. The report details USTR’s unilateral standards for the granting and enforcement for a diverse set of intellectual property rights, and singles out countries that USTR claims do not… Continue Reading →

Senate HELP Committee proposes evaluation of Innovation Inducement Prizes, as alternative to product monopolies

Posted on April 25, 2012 by James Love

In the United States Senate, the Committee on Health, Education, Labor and Pensions (HELP) is trying to move forward a bill titled the “Food and Drug Administration Safety and Innovation Act.” Among other things, the bill would “amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, establish user-fee programs for generic drugs and biosimilars,” and address a number of other topics, such as extend the legal monopoly on antibiotic drugs by 5 years. Continue Reading →

The 2012 WIPO/Library of Congress International Copyright Training symposium for developing countries

Posted on March 21, 2012 by James Love

This week WIPO and the Library of Congress are holding a week long symposium on International Copyright, with title:

Emerging Issues in Copyright and Related Rights for Developing
Countries and Countries with Economies in Transition
organized by
the World Intellectual Property Organization (WIPO)
in cooperation with
the United States Copyright Office, Library of Congress
Washington D.C., March 19 to 23, 2012

Continue Reading →

History of 28 USC 1498, as reported in Zoltek Corp v US (2009-5135)

Posted on March 14, 2012 by James Love

This March 14, 2012 opinion by the United States Court of Appeals for the Federal Circuit provides a discussion of some elements of the history of 28 USC 1498, beginning in 1894, through changes in the law in 1910, 1918,… Continue Reading →

1

KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)

Posted on March 12, 2012 by James Love

The India Controller General Controller General of Patents, Designs & Trade Marks has just (March 12, 2012) issued an order granting a compulsory license to patents on the cancer drug sorafenib/Nexavar, in the matter of NATCO Vs. BAYER. A copy of the decision is attached below.

Continue Reading →

What’s (still) wrong with ACTA, and why governments should reject the illegitimate agreement

Posted on February 26, 2012 by James Love

This is a blog about the Anti-Counterfeiting Trade Agreement (ACTA). More information is available here: /acta

ACTA is an attempt to bypass multilateral institutions

Continue Reading →

IIPA Special 301 complaints regarding unauthorized copying of textbooks and other educational materials

Posted on February 26, 2012 by James Love

USTR asked to use trade pressure to curtail unauthorized copying of educational materials

Continue Reading →

Size Matters: PhRMA’s Special 301 picks for South America.

Posted on February 25, 2012 by James Love

Every year, USTR publishes the names of countries that do not adequately protect intellectual property rights. (See /ustr/special301) . Among the classifications are the Priority Watch List (PWL) and the somewhat lower status Watch List (WL).

Continue Reading →

Total expenses vs reported expenditures on lobbying, six trade associations that lobby on IPR

Posted on February 22, 2012 by James Love

President Obama claims to have kept “lobbyists” off the advisory boards for USTR. The Obama Administration relies upon the narrow legal definition of those persons who register to lobby the US Congress, which excludes expenditures to direct, supervise or support the lobbyists, and expenditures of many staff and consultants who are not fully engaged in lobbying the Congress. Expenditures to influence the executive branch (including USTR) has very little if any regulation, and are not counted as lobbying. Continue Reading →

Author: James Love

Is the WHO CEWG proposal for the R&D treaty “too small”?

USTR’s 2012 Special 301 Report, focuses on largest developing country markets, and Canada

Senate HELP Committee proposes evaluation of Innovation Inducement Prizes, as alternative to product monopolies

The 2012 WIPO/Library of Congress International Copyright Training symposium for developing countries

History of 28 USC 1498, as reported in Zoltek Corp v US (2009-5135)

KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)

What’s (still) wrong with ACTA, and why governments should reject the illegitimate agreement

ACTA is an attempt to bypass multilateral institutions

IIPA Special 301 complaints regarding unauthorized copying of textbooks and other educational materials

USTR asked to use trade pressure to curtail unauthorized copying of educational materials

Size Matters: PhRMA’s Special 301 picks for South America.

Total expenses vs reported expenditures on lobbying, six trade associations that lobby on IPR

Categories